DDrare: Database of Drug Development for Rare Diseases

Searched query = "Alveolar hypoventilation syndrome", "AHS", "Hypoventilation syndrome", "OHS", "CCHS", "Idiopathic central alveolar hypoventilation", "ICAH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Acetazolamide; Cerazette; Desogestrel; Domperidone; Désogestrel; Equal; Gold; Ketogenic Diet; Motilium; Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.; Other: BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01500473 (ClinicalTrials.gov)	February 2012	22/12/2011	Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome	Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome	Congenital Central Hypoventilation Syndrome	Drug: Desogestrel	Children's Hospital Los Angeles	NULL	Not yet recruiting	16 Years	50 Years	Female	8	N/A	United States
2	NCT01243697 (ClinicalTrials.gov)	April 2011	17/11/2010	Assessment of Desogestrel in Ondine Syndrome	Assessment of Desogestrel for a Pharmacological Recovery of Ventilatory Activity in Congenital Central Hypoventilation Syndrome - Ondine Syndrome	Ondine Syndrome	Drug: desogestrel	Assistance Publique - Hôpitaux de Paris	NULL	Completed	10 Years	60 Years	Female	6	Phase 2;Phase 3	France
3	EUCTR2011-000989-35-FR (EUCTR)		06/05/2011	N/A	N/A - RESPIRONDINE	MedDRA version: 14.0;Level: PT;Classification code 10066131;Term: Congenital central hypoventilation syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders	Trade Name: Cerazette Product Name: Cerazette INN or Proposed INN: Désogestrel	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)	NULL	NA			Female: yes Male: no		Phase 2	France

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01500473
(ClinicalTrials.gov)

February 2012

22/12/2011

Therapeutic Effect of Desogestrel on Ventilatory Control in Patients With Congenital Central Hypoventilation Syndrome

Congenital Central Hypoventilation Syndrome

Drug: Desogestrel

Children's Hospital Los Angeles

NULL

Not yet recruiting

16 Years

50 Years

Female

N/A

United States

NCT01243697
(ClinicalTrials.gov)

April 2011

17/11/2010

Assessment of Desogestrel in Ondine Syndrome

Assessment of Desogestrel for a Pharmacological Recovery of Ventilatory Activity in Congenital Central Hypoventilation Syndrome - Ondine Syndrome

Ondine Syndrome

Drug: desogestrel

Assistance Publique - Hôpitaux de Paris

NULL

Completed

10 Years

60 Years

Female

Phase 2;Phase 3

France

EUCTR2011-000989-35-FR
(EUCTR)

06/05/2011

N/A

N/A - RESPIRONDINE

MedDRA version: 14.0;Level: PT;Classification code 10066131;Term: Congenital central hypoventilation syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders

Trade Name: Cerazette
Product Name: Cerazette
INN or Proposed INN: Désogestrel

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)

NULL

Female: yes
Male: no

Phase 2

France